TRULANCE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for TRULANCE (TRULANCE).
Guanylate cyclase-C receptor agonist; increases intracellular cGMP, leading to chloride and water secretion into intestinal lumen and accelerated transit.
| Metabolism | Metabolized by hydrolysis and reduction, not via cytochrome P450; converted to active and inactive metabolites. |
| Excretion | Primarily excreted in feces as unchanged drug (approximately 60%) and as metabolites; renal excretion is minimal (<3%). |
| Half-life | Terminal elimination half-life is approximately 16 hours, supporting once-daily dosing. |
| Protein binding | Approximately 95% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Volume of distribution is approximately 2.3 L/kg, indicating extensive tissue distribution. |
| Bioavailability | Absolute bioavailability is approximately 19% after oral administration due to first-pass metabolism. |
| Onset of Action | Oral: Onset within 24 hours of first dose; clinical effect on bowel movements observed within the first week. |
| Duration of Action | Duration is approximately 24 hours with once-daily dosing; sustained increase in spontaneous bowel movements over 12 weeks in clinical trials. |
3 mg orally once daily.
| Dosage form | TABLET |
| Renal impairment | No dose adjustment required for any degree of renal impairment, including end-stage renal disease. |
| Liver impairment | No dose adjustment required for mild or moderate hepatic impairment (Child-Pugh class A or B). Not studied in severe hepatic impairment (Child-Pugh class C); use not recommended. |
| Pediatric use | Safety and efficacy not established in pediatric patients below 18 years of age. |
| Geriatric use | No specific dose adjustment recommended; however, consider potential increased sensitivity and monitor renal function due to age-related decline. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for TRULANCE (TRULANCE).
| Breastfeeding | No data on presence in human milk, effects on breastfed infant, or milk production. Exercise caution; consider developmental and health benefits of breastfeeding alongside maternal need for TRULANCE. |
| Teratogenic Risk | No adequate and well-controlled studies in pregnant women. Animal studies show no evidence of harm at clinically relevant exposures. Risk cannot be ruled out; use only if clearly needed. |
| Fetal Monitoring |
■ FDA Black Box Warning
Not applicable.
| Serious Effects |
["Known or suspected mechanical gastrointestinal obstruction; pediatric patients <2 years of age; hypersensitivity to linaclotide or any component of the formulation."]
| Precautions | ["Risk of diarrhea, sometimes severe; avoid in patients with suspected or known mechanical gastrointestinal obstruction; caution in patients with severe hepatic impairment."] |
Loading safety data…
| No specific monitoring requirements beyond routine prenatal care. Monitor for gastrointestinal adverse effects (e.g., diarrhea) and maternal hydration status. |
| Fertility Effects | No human data on fertility. Animal studies show no impairment of fertility at clinically relevant exposures. |